A History of Outperforming Analyst Forecasts and Beating the Odds: Maravai LifeSciences Holdings Inc. (MRVI)

Maravai LifeSciences Holdings Inc. (NASDAQ: MRVI) stock fell -6.41% on Tuesday to $13.58 against a previous-day closing price of $14.51. With 2.25 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.99 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $14.43 whereas the lowest price it dropped to was $13.46. The 52-week range on MRVI shows that it touched its highest point at $41.82 and its lowest point at $12.16 during that stretch. It currently has a 1-year price target of $23.18.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of MRVI was down-trending over the past week, with a drop of -1.38%, but this was down by -3.82% over a month. Three-month performance dropped to -18.59% while six-month performance fell -46.39%. The stock lost -44.48% in the past year, while it has lost -5.10% so far this year. A look at the trailing 12-month EPS for MRVI yields 2.35 with Next year EPS estimates of 0.39. For the next quarter, that number is 0.34. This implies an EPS growth rate of 422.90% for this year and -78.37% for next year.

Float and Shares Shorts:

At present, 131.54 million MRVI shares are outstanding with a float of 109.24 million shares on hand for trading. On Oct 13, 2022, short shares totaled 4.47 million, which was 3.40% higher than short shares on Sep 14, 2022. In addition to Mr. Carl W. Hull as the firm’s Co-Founder and Exec. Chairman & Interim CEO, Mr. Kevin M. Herde serves as its Exec. VP & CFO.


Institutional Ownership:

Through their ownership of 102.31% of MRVI’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 44.54% of MRVI, in contrast to 34.05% held by mutual funds. Shares owned by individuals account for 17.11%. As the largest shareholder in MRVI with 10.76% of the stake, Massachusetts Financial Services holds 14,150,891 shares worth 14,150,891. A second-largest stockholder of MRVI, Select Equity Group LP, holds 11,521,575 shares, controlling over 8.76% of the firm’s shares. The Vanguard Group, Inc. is the third largest shareholder in MRVI, holding 10,061,696 shares or 7.65% stake. With a 2.57% stake in MRVI, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 3,378,339 shares are owned by the mutual fund manager. The American Century Ultra Fund, which owns about 2.51% of MRVI stock, is the second-largest Mutual Fund holder. It holds 3,302,000 shares valued at 47.25 million. MFS Mid Cap Growth Fund holds 2.48% of the stake in MRVI, owning 3,261,893 shares worth 46.68 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for MRVI since 12 analysts follow the stock currently. There are 9 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With MRVI analysts setting a high price target of $32.00 and a low target of $16.00, the average target price over the next 12 months is $23.18. Based on these targets, MRVI could surge 135.64% to reach the target high and rise by 17.82% to reach the target low. Reaching the average price target will result in a growth of 70.69% from current levels.


EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. MRVI will report FY 2022 earnings on 02/22/2024. Analysts have provided yearly estimates in a range of $1.83 being high and $1.77 being low. For MRVI, this leads to a yearly average estimate of $1.79. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Maravai LifeSciences Holdings Inc. surprised analysts by $0.04 when it reported $0.37 EPS against a consensus estimate of $0.33. The surprise factor in the prior quarter was $0.09. Based on analyst estimates, the high estimate for the next quarter is $0.37 and the low estimate is $0.32. The average estimate for the next quarter is thus $0.34.

Summary of Insider Activity:

Insiders traded MRVI stock several times over the past three months with 3 Buys and 0 Sells. In these transactions, 1,158 shares were bought while 0 shares were sold. The number of buy transactions has increased to 18 while that of sell transactions has risen to 3 over the past year. The total number of shares bought during that period was 568,263 while 13,300 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *